Table 4.

TEAEs Potentially Related to Systemic VEGF Inhibition (Safety Population)

TEAE	Abicipar Q8 (N=123), n (%)
Overall	13 (10.6)
Hypertension	7 (5.7)
Cerebrovascular accident	1 (0.8)
Hematoma	1 (0.8)
Hematuria	1 (0.8)
Hemorrhoidal hemorrhage	1 (0.8)
Protein urine present	1 (0.8)
Proteinuria	1 (0.8)

Notes: All special interest TEAEs potentially related to systemic VEGF inhibition are presented, regardless of relationship to treatment. Preferred terms are sorted by descending frequency. Within each preferred term, a patient is counted at most once.

Abbreviations: TEAE, treatment-emergent adverse event; VEGF, vascular endothelial growth factor.